Two more for AtCor
Monday, 08 December, 2008
Medical device company AtCor has signed two new supply agreements worth US$1.5 million for its reflected blood pressure measurement system SphygmoCor.
The new agreements cap an excellent six months for the Sydney company, with supply contracts signed in the period worth US$5.7 million.
The device is aimed at both clinical practice and clinical trials to understand drug efficacy and mechanisms of action.
The SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
